“We are in a time of great hope in ALS therapy development. The efforts highlighted here are poised to accelerate progress in clinical trials and to bring new treatments to people living with ALS.” – Barb Newhouse, President and CEO, The ALS Association
Collaboration is a cornerstone of The ALS Association’s global research program. That’s why The Association hosts an annual ALS Drug Company Working Group that brings together representatives from pharmaceutical companies and academia to discuss how to move ALS research and therapy development forward.
This year, the Working Group was held at the 68th Annual American Academy of Neurology (AAN) Meeting in Vancouver in April. Below are some of the highlights from the meeting.